Economic Evaluations of Strategies for Preventing Renal Disease in Non-Insulin Dependent Diabetes Mellitus

  • Diane L. Manninen
  • Erik J. Dasbach
  • Frederick B. Dong
  • Ronald E. Aubert
  • Steven M. Teutsch
  • William H. Herman


Recent clinical trials such as the Stockholm Diabetes Intervention Study (SDIS) and the Diabetes Control and Complications Trial (DCCT) have demonstrated that intensive glycaemic control can slow the development and delay the progression of renal disease in persons with insulin dependent diabetes mellitus (IDDM) [1,2]. In addition, clinical studies suggest that treatment of patients with microalbuminuria and clinical nephropathy with angiotensin-converting enzyme (ACE) inhibitors and other antihypertensive agents [3–8] or with a low protein diet [9–12] can slow progression to end-stage renal disease. However, few studies have demonstrated the efficacy of such interventions in persons with non-insulin dependent diabetes mellitus (NIDDM).


Economic Evaluation Diabetic Nephropathy Health Care Financing NIDDM Patient Intervention Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304–309.PubMedCrossRefGoogle Scholar
  2. 2.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.CrossRefGoogle Scholar
  3. 3.
    Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin-converting-enzyme inhibition on nephropathy. N Engl J Med 1993; 329: 1456–1462.PubMedCrossRefGoogle Scholar
  4. 4.
    Wiegman TB, Herron KG, Chonko AM, MacDougall ML, Moore WV. Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients. Diabetes 1992; 41: 62–67.CrossRefGoogle Scholar
  5. 5.
    Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.PubMedCrossRefGoogle Scholar
  6. 6.
    Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of Captopril in postponing nephropathy in normotensive insulin dependent patients with microalbuminuria. BMJ 1991; 303: 81–87.PubMedCrossRefGoogle Scholar
  7. 7.
    Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685–688.PubMedCrossRefGoogle Scholar
  8. 8.
    Christensen CK, Mogensen CE. Antihypertensive treatment: long-term reversal of progression of albuminuria in incipient diabetic nephropathy. A longitudinal study of renal function. J Diabetic Complications 1987; 1: 45–52.CrossRefGoogle Scholar
  9. 9.
    Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 78–84.PubMedCrossRefGoogle Scholar
  10. 10.
    Jibani MM, Bloodworth LL, Foden E, Griffiths KD, Galpin OP. Predominantly vegetarian diet in patients with incipient and early clinical diabetic nephropathy: Effects on albumin excretion rate and nutritional status. Diabetic Med 1991; 8: 949–953.PubMedCrossRefGoogle Scholar
  11. 11.
    Evanoff GV, Thompson CS, Brown J, Weinman EJ. The effect of dietary protein restriction on the progression of diabetic nephropathy. Arch Intern Med 1987; 147: 492–495.PubMedCrossRefGoogle Scholar
  12. 12.
    Wiseman MJ, Bognetti E, Dodds R, Keen H, Viberti GC. Changes in renal function in response to protein restricted diet in type 1 (insulin-dependent) diabetic patients. Diabetologia 1987; 30: 154–159.PubMedCrossRefGoogle Scholar
  13. 13.
    Drummond MF, Davies LM, Ferris FL III. Assessing the costs and benefits of medical research: the Diabetic Retinopathy Study. Soc Sei Med 1992; 34: 973–981.CrossRefGoogle Scholar
  14. 14.
    Detsky AS. Using economic analysis to determine the resource consequences of choices made in planning clinical trials. J Chron Dis 1985; 38: 733–765.CrossRefGoogle Scholar
  15. 15.
    Detsky AS. Are clinical trials a cost-effective investment? JAMA 1989; 262: 1795–1800.PubMedCrossRefGoogle Scholar
  16. 16.
    Weinstein MC. Cost-effective priorities for cancer prevention. Science 1983; 221: 17–23PubMedCrossRefGoogle Scholar
  17. 17.
    Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992; 3: S111–S119.Google Scholar
  18. 18.
    Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes? BMJ 1993; 306: 1722–1725.PubMedCrossRefGoogle Scholar
  19. 19.
    Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321: 1074–1079.PubMedCrossRefGoogle Scholar
  20. 20.
    Feldman HI, Klag MJ, Chiapella AP, Whelton PK. End-stage renal disease in US minority groups. Am J Kidney Dis 1992; 19: 397–410.PubMedGoogle Scholar
  21. 21.
    Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ. The excess incidence of diabetic end-stage renal disease among blacks. JAMA 1992; 268: 3079–3084.PubMedCrossRefGoogle Scholar
  22. 22.
    Newman JM, Marfin AA, Eggers PW, Helgerson SD. End state renal disease among Native Americans, 1983–1986. Am J Public Health 1990; 80: 318–319.PubMedCrossRefGoogle Scholar
  23. 23.
    Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL, Pettitt DJ, Moffett CD, Teutsch SM, Bennett PH. Incidence of end-stage renal disease in Type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1988; 31: 730–736.PubMedCrossRefGoogle Scholar
  24. 24.
    Haffner SM, Mitchell BD, Pugh JA, Stern MP, Kozlowski MK, Hazuda HP, Patterson JK, Klein R. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care 1989; 12: 530–536.PubMedCrossRefGoogle Scholar
  25. 25.
    Pugh JA, Stern MP, Haffner SM, Eitler CW, Zapata M. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol 1988; 127: 135–144.PubMedGoogle Scholar
  26. 26.
    Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815–819.PubMedCrossRefGoogle Scholar
  27. 27.
    Ballard DJ, Humphrey LL, Melton LJ III, Frohnert PP, Chu CP, O’Fallon WM, Palumbo PJ. Epidemiology of persistent proteinuria in type II diabetes mellitus. Diabetes 1988; 37: 405–412.PubMedCrossRefGoogle Scholar
  28. 28.
    United States Renal Data System. USRDS 1993 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1993.Google Scholar
  29. 29.
    Health Care Financing Administration. Research Report: End Stage Renal Disease, 1991. HCFA Publ. No. 03338. Baltimore, MD: Health Care Financing Administration; 1993.Google Scholar
  30. 30.
    Health Care Financing Administration. List of Top 200 Procedure Codes Ranked by Allowed Charges from the Completed Year 1990. Baltimore, MD: Health Care Financing Administration; 1992.Google Scholar
  31. 31.
    Medicare Fee Schedule. Federal Register, November 25, 1992; 57: 55896–56230.Google Scholar
  32. 32.
    Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sei Med 1989; 28: 299–308.CrossRefGoogle Scholar
  33. 33.
    Mehrez A, Gafni A. Quality adjusted life years utility theory and healthy years equivalent. Med Decis Making 1989; 9: 142–149.PubMedCrossRefGoogle Scholar
  34. 34.
    Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978; 31: 697–704.PubMedCrossRefGoogle Scholar
  35. 35.
    Churchill DN, Torrance GW, Taylor W, Barnes CC, Ludwin D, Shimizu A, Smith EKM. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987; 10: 14–20.PubMedGoogle Scholar
  36. 36.
    Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialy-sis. BMJ 1990; 300: 573–578.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Diane L. Manninen
  • Erik J. Dasbach
  • Frederick B. Dong
  • Ronald E. Aubert
  • Steven M. Teutsch
  • William H. Herman

There are no affiliations available

Personalised recommendations